National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.
about
Pharmacogenomics and cardiovascular diseasePharmacogenomics discovery and implementation in genome-wide association studies eraClinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingAnticoagulation drug therapy: a reviewCare transitions in anticoagulation management for patients with atrial fibrillation: an emphasis on safetyChanges in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011An evaluation of intravenous vitamin k for warfarin reversal: are guideline recommendations being followed?Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapyBleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study.Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversalTransRadial Education and Therapeutics (TREAT): shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention: a report from the Cardiac Safety Research Consortium.Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients.Novel oral anticoagulants and their role in clinical practice.Prediction of warfarin dose: why, when and how?Adverse drug events as a cause of hospitalization in older adults.Impact of target-specific oral anticoagulants on transitions of care and outpatient care models.Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array.Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.Four-Factor Prothrombin Complex Concentrate Reduces Time to Procedure in Vitamin K Antagonist-Treated Patients Experiencing Gastrointestinal Bleeding: A Post Hoc Analysis of Two Randomized Controlled Trials.Factors influencing recurrent emergency department visits for epistaxis in the elderly.The Impact of Gene Polymorphisms on Anticoagulation Control With Warfarin.Effect of gene polymorphims on the warfarin treatment at initial stage.Treatment algorithm for oral anticoagulant and antiplatelet therapy in epistaxis patients.Warfarin in Complex Older Patients: Have we Reached a Tipping Point?3-Factor Versus 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal in Severe Bleeding: A Multicenter, Retrospective, Propensity-Matched Pilot Study.Axillary artery tumor embolism secondary to mitral valve myxosarcoma in a dog.
P2860
Q26997380-035B90BF-DD0C-4365-93A0-B980A100250FQ27001573-8B5B9CA0-C437-4698-81F0-B7E5AC45D593Q27008360-70E07B4C-7D09-4264-9D6B-834D2EF03E6DQ27021871-A63C7049-79C7-4B5A-B5D4-40B3D025ECA1Q27025527-D060C757-DBDE-4B96-9139-39E331F21E5AQ28109335-7CB602A6-4297-44EB-9706-258A57607A32Q35063096-D79AF54C-BE68-4495-A81B-1620929DC088Q35373624-4956646D-8E13-4983-9CCF-F97E507C549FQ35707491-0DC8D19E-3632-492D-A774-70A6F00A92EFQ36584522-7CDD809E-726D-4009-B597-7B5F09F1E28FQ37457934-1DDD06B2-B113-405A-90AE-9D450FA8C7DAQ37492073-14444805-0553-44F8-BECA-739CD62A161AQ37961824-AF8108BC-0CD9-4F24-9B93-F3D344573012Q37989489-13F0E58E-56C4-4722-929A-DFE10339912AQ38085222-317C16E7-4AE8-4279-B547-FFE3962D5B3CQ38088202-42C44E83-1AA0-403F-91AC-E449C5A73890Q38961083-A2EB4A78-2D90-4F13-B158-7C7AE66A3650Q40132047-54471522-D5D9-47B3-A762-E0D306B67579Q42335970-93C5EFC4-569D-4E36-BFBA-E57314A42C59Q46516369-D1F4CD3F-8AF1-4C6B-BAB9-89E4F3D9632FQ47363721-A5E73E58-B8B8-4283-800C-8F0EEBB47608Q48665970-52976F76-1880-4706-9122-648CA14FB8AFQ48905886-963B9FD8-9FDE-4FA1-898B-A6D4DE4772E6Q50862515-F031274C-1134-4B88-A034-54719D70A538Q52766999-AE129256-9358-4038-857E-DA469A508029Q53343255-84179612-D437-47C6-AAE4-B17051096C82Q53671754-EB796A1C-5F92-47F6-9E4B-C221CAF32DDF
P2860
National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
National estimates of emergenc ...... lus aspirin and from warfarin.
@ast
National estimates of emergenc ...... lus aspirin and from warfarin.
@en
National estimates of emergenc ...... lus aspirin and from warfarin.
@nl
type
label
National estimates of emergenc ...... lus aspirin and from warfarin.
@ast
National estimates of emergenc ...... lus aspirin and from warfarin.
@en
National estimates of emergenc ...... lus aspirin and from warfarin.
@nl
prefLabel
National estimates of emergenc ...... lus aspirin and from warfarin.
@ast
National estimates of emergenc ...... lus aspirin and from warfarin.
@en
National estimates of emergenc ...... lus aspirin and from warfarin.
@nl
P1476
National estimates of emergenc ...... plus aspirin and from warfarin
@en
P2093
Laurence S Sperling
Scott R Kegler
P304
P356
10.1001/ARCHINTERNMED.2010.407
P407
P577
2010-11-01T00:00:00Z